Eisai Korea Inc.
Clinical trials sponsored by Eisai Korea Inc., explained in plain language.
The Korean subsidiary of Eisai, a Japanese pharmaceutical company.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New study tracks Real-World safety of arthritis and colitis drug in korea
Disease control Recruiting nowThis study is monitoring the safety and effectiveness of the drug Jyseleca (filgotinib) in Korean patients with rheumatoid arthritis or ulcerative colitis. Researchers will track side effects and disease activity over 24 weeks. About 2,040 participants are being observed during r…
Sponsor: Eisai Korea Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Alzheimer's drug LEQEMBI under 6-Year safety watch in 3,000 patients
Disease control Recruiting nowThis study will follow 3,000 South Korean Alzheimer's patients taking LEQEMBI for up to 6 years to monitor safety, especially brain swelling or bleeding. Researchers will use real-world data from a national registry. The goal is to understand how often these side effects occur in…
Sponsor: Eisai Korea Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC